| Literature DB >> 35056148 |
Marjan Majdinasab1, Mihaela Badea2, Jean Louis Marty3.
Abstract
The lateral flow assay (LFA) is an extensively used paper-based platform for the rapid and on-site detection of different analytes. The method is user-friendly with no need for sophisticated operation and only includes adding sample. Generally, antibodies are employed as the biorecognition elements in the LFA. However, antibodies possess several disadvantages including poor stability, high batch-to-batch variation, long development time, high price and need for ethical approval and cold chain. Because of these limitations, aptamers screened by an in vitro process can be a good alternative to antibodies as biorecognition molecules in the LFA. In recent years, aptamer-based LFAs have been investigated for the detection of different analytes in point-of-care diagnostics. In this review, we summarize the applications of aptamer technology in LFAs in clinical diagnostic rapid tests for the detection of biomarkers, microbial analytes, hormones and antibiotics. Performance, advantages and drawbacks of the developed assays are also discussed.Entities:
Keywords: aptamer; biomarker; clinical; lateral flow assay; rapid test
Year: 2022 PMID: 35056148 PMCID: PMC8781427 DOI: 10.3390/ph15010090
Source DB: PubMed Journal: Pharmaceuticals (Basel) ISSN: 1424-8247
Figure 1(a) Basic structure of a lateral flow test strip; (b) Principle of two common formats of LFA including sandwich and competitive formats. Reprinted with permission from [18,19], respectively.
Figure 2Principle of (a) sandwich aptamer-based LFA for the detection of thrombin; (b) competitive aptamer-based LFA for the detection of ochratoxin A. Reproduced with permission from [28,29], respectively.
Figure 3(a) A schematic representation of the duplex dissociation mechanism for the detection of dopamine. (b) Adsorption–desorption colorimetric LFA for HER2. (c) An aptamer-based competitive LFA using gold nanozyme as a label for the detection of CA125. (d) An aptamer-based hook-effect-recognizable three-line lateral flow biosensor for rapid detection of thrombin. Reprinted with permission from [37,38,40,41], respectively.
Aptamer-based lateral flow assays for detection of biomarkers.
| Strategy | Biomarker | Label | Test Line | Control Line | LOD | Detection Range | Matrix | Ref. |
|---|---|---|---|---|---|---|---|---|
| Conjugation of AuNPs with dopamine duplex aptamer and dissociation of duplex in the presence of target | Dopamine | AuNPs | Streptavidin-biotinylated cDNA3 | Streptavidin-biotinylated cDNA1 | 50 ng mL−1 | nr * | Urine | [ |
| Desorption of biotin-modified aptamer from AuNPs surface in the presence of analyte | HER2 | AuNPs | Streptavidin and pullulan mixture | Cationic charged PDDA polymer | 20 nM | nr | Human serum | [ |
| Competitive reaction between CA125 conjugated with AuNPs and unlabeled CA125 for binding to capture probe | CA125 | AuNPs nanozyme | CA125 specific aptamer | - | 5.21 U mL−1 | 7.5–200 U mL−1 | Human serum | [ |
| An aptamer-based hook-effect-recognizable three-line LFA | Thrombin | AuNPs | A biotinylated aptamer with poly A tail (T-DNA) | A biotinylated poly T oligonucleotide probe (C-DNA) | 0.85 nM | 1 nM–100 µM | Human serum | [ |
| Binding of a biotinylated aptamer to target in the sample and reaction with AuNPs-streptavidin conjugate, then subsequent capturing by the | Osteopontin | AuNPs | Osteopontin antibody | Complementary ssDNA | 0.1 ng mL−1 | 10–500 ng mL−1 | Human serum | [ |
| A sandwich LFA based on biotin-labeled primary aptamer immobilized on streptavidin coated membrane as a capturing probe and secondary aptamer conjugated with AuNPs as a signaling probe. | Vaspin | AuNPs | Streptavidin-biotinylated aptamer | Streptavidin-biotinylated complementary aptamer | 0.105 nM | 0.105–25 nM | Human serum | [ |
| Aptamer-quantum dot conjugate towards thrombin, and antibody-quantum dot conjugate against interleukin-6 | Thrombin | Green and red quantum dots | Streptavidin-biotinylated aptamer against thrombin | Anti-mouse antibody | 3 nM | nr | Human serum | [ |
| Visual multiple recognition of protein biomarkers based on an array of aptamer- modified AuNPs | Thrombin | AuNPs | T1: Streptavidin | Streptavidin-biotinylated thrombin control DNA | 1.61 nM | 3.2–250 nM | Human serum | [ |
* nr: not reported.
Figure 4(a) Principle of aptamer-exonuclease III (Exo III)-assisted amplification-based LFA for the detection of E. coli O157:H7: (A) in the presence of target; (B) in the absence of target; (b) A LFA based on aptamer-gated silica nanoparticles and release of signal molecules for the detection of Listeria monocytogenes; (c) whole virus particle detection using a sandwich LFA. Reprinted with permission from [49,50,51], respectively.
Aptamer-based lateral flow assays for detection of microbial analytes.
| Strategy | Microbial Analyte | Label | Test Line | Control Line | LOD | Detection Range | Matrix | Ref. |
|---|---|---|---|---|---|---|---|---|
| Combining | AuNPs | Biotinylated poly T oligonucleotide probe | Biotinylated complementary sequence to the AuNPs probes | 7.6 × 101 cfu mL−1 | 102–106 cfu mL−1 | Culture media | [ | |
| Aptamer-gated release of TMB as signal molecule and HRP activity to generate signal |
| Silica nanoparticles | Immobilized HRP | No control line | 53 cells mL−1 | nr | Chicken | [ |
| Sandwich LFA for the detection of whole virus particles | Avian influenza H5N2 | AuNPs | Biotin modified primary aptamer | Biotin modified poly A sequence | 1.2 × 106 EID50 mL−1 | 1.2 × 106 EID50 mL−1–1 × 107 EID50 mL−1 | Duck’s feces | [ |
| A dual recognition element LFA using both aptamer and antibody | Influenza virus (strain A/H3N2/Panama/2007/99) | AuNPs | Streptavidin | Antibody | 2 × 106 virus particle | - | - | [ |
| Pre-enrichment with magnetic nanoparticles conjugated with aptamer–ssDNA1and detection of released ssDNA1using LFA strip and AuNPs capture probe | AuNPs | Streptavidin-biotin modified ssDNA complementary with ssDNA1 | Streptavidin-biotin modified poly A ssDNA complementary with poly T ssDNA on AuNPs surface | 4.1 × 102 cfu mL−1 | 8.6 × 102–8.6 × 107 cfu mL−1 | Milk | [ | |
| Complex formation between AuNPs-aptamer1 conjugate, analyte and apatmer 2 immobilized on the test line | AuNPs | Streptavidin-biotin modified aptamer2 | Streptavidin-biotin modified complementary DNA with AuNPs-aptamer conjugate | 5 × 103 cfu mL−1 | nr | Food samples | [ |
Figure 5(a) A LFA based on adsorption–desorption of an aptamer on the surface of AuNPs for cortisol detection; (b) A LFA based on AuNPs conjugated with a duplex aptamer for the detection of cortisol in saliva. Reproduced from [56,57], respectively, with permission.
Aptamer-based lateral flow assays for detection of hormones.
| Strategy | Hormone | Label | Test Line | Control Line | LOD | Detection Range | Matrix | Ref. |
|---|---|---|---|---|---|---|---|---|
| Desorption of specific aptamer from AuNPs surface in the presence of target molecule | Cortisol | AuNPs | Cysteamine | - | 1 ng mL−1 | nr | Sweat | [ |
| Dissociation of specific aptamer from duplex probe conjugated with AuNPs in the presence of target | Cortisol | AuNPs | Biotin-modified oligonucleotide probe | Biotin-modified poly A probe | 0.37 ng mL−1 | 0.5–15 ng mL−1 | Salivary | [ |
| Dissociation of specific aptamer from duplex probe conjugated with AuNPs in the presence of target | Progesterone | AuNPs | Streptavidin | - | 5 nM | nr | Water | [ |
Figure 6(a) Schematic representation of magnetic microsphere-assisted LFA for kanamycin detection; (b) A competitive aptamer-based LFA for the detection of oxytetracycline; (c) A competitive aptamer-based LFA for ampicillin detection. Reprinted from [62,63,64], respectively, with permission.
Aptamer-based lateral flow assays for detection of antibiotics.
| Strategy | Antibiotic | Label | Test Line | Control Line | LOD | Detection Range | Matrix | Ref. |
|---|---|---|---|---|---|---|---|---|
| Magnetic sepration of analyte by aptamer-cDNA duplex conjugated with magnetic microspheres; then detection of cDNA by LFA strip | Kanamycin | AuNPs | Streptavidin-biotin-capture DNA1 | Streptavidin-biotin-capture DNA2 | 4.96 nm | 5–500 nM | Milk, milk products, honey | [ |
| Competitive reaction between analyte in sample and analyte-career protein conjugate on the test line for binding to AuNPs-aptamer | Oxytetracycline | AuNPs | Oxytetracycline-carrier protein | Biotin-modified complementary probe | 5 ng mL−1 | nr | Milk | [ |
| Competitive reaction between analyte in sample and C-reactive protein conjugated with biotin for binding to AuNPs-aptamer-mFc | Ampicillin | AuNPs | Streptavidin | α-mouse antibody | 185 mg L−1 | nr | Milk | [ |
| Complex formation between analyte in sample, labeled DNA on conjugate pad and capture DNA on the test line | Ampicillin | Hexachloro-6-carboxyfluorescein | Biotin-modified ampicillin capture DNA | - | 0.06 ng L−1 | 0.5–500 ng L−1 | Water | [ |